Welcome to our dedicated page for Biolargo SEC filings (Ticker: BLGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
From PFAS-remediating water systems to next-gen molten-salt batteries, BioLargo’s business touches highly regulated industries, so its disclosures run deep. BioLargo insider trading Form 4 transactions, segment details buried in a BioLargo quarterly earnings report 10-Q filing, or sudden BioLargo 8-K material events explained across dozens of exhibits can consume hours.
Stock Titan delivers BioLargo SEC filings explained simply. Our AI ingests every document the moment it posts to EDGAR, surfaces BioLargo Form 4 insider transactions real-time, and pairs an earnings report filing analysis with concise notes on cash needs for scale-up. Jump straight to BioLargo executive stock transactions Form 4, or scan a BioLargo annual report 10-K simplified to spotlight PFAS remediation milestones. AI-generated ratio tables, keyword search, side-by-side quarter comparisons, and expert context dramatically speed up your workflow.
Need the BioLargo proxy statement executive compensation tables to assess R&D incentives, or guidance for understanding BioLargo SEC documents with AI before the next capital raise? Our summaries isolate non-recurring charges, carbon-reduction commitments, and backlog disclosures so you can model value drivers quickly. Whether you monitor liquidity for water-treatment rollouts or track licensing revenue milestones, the complete archive updates in real time—saving the deep dive while keeping the detail.
BioLargo, Inc. (BLGO) furnished investor presentation materials under Item 7.01 (Regulation FD). The company plans to present the slides attached as Exhibit 99.1 at the LD Micro Main Event XIX at the Hotel del Coronado in San Diego on October 20 at 2:00 p.m. Pacific Time.
The information in Item 7.01 and Exhibit 99.1 is furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, is not incorporated by reference into other SEC filings, and may be updated through future public disclosures.
Jack B. Strommen, a director of BioLargo, Inc. (BLGO), received an option grant of 88,235 shares on 09/30/2025 under the company's 2024 Equity Incentive Plan. The option has an exercise price of $0.17 per share, is exercisable beginning 09/30/2025, and expires 09/30/2035. After this grant, Mr. Strommen directly beneficially owns 2,278,121 shares of common stock. The filing states the option was issued as payment for $15,000 of board fees for the most recently completed quarterly period. The Form 4 was signed by an attorney-in-fact on 10/02/2025 and is reported as an individual filing by one reporting person.
Linda Park, a director of Biolargo, Inc. (BLGO), received 110,294 stock options on 09/30/2025 at a $0.17 exercise price that vest/exercise beginning 09/30/2025 and expire 09/30/2035. The filing shows she now directly beneficially owns 1,164,025 shares of common stock after the reported transaction. The options were issued as payment for $18,750 of board fees under the Issuer's 2024 Equity Incentive Plan. The Form 4 was filed by one reporting person and signed by an attorney-in-fact on 10/02/2025.
Christina Elaine Bray, a director of Biolargo, Inc. (BLGO), received an option to purchase 110,294 shares of common stock at an exercise price of $0.17 per share on 09/30/2025. The option is exercisable on 09/30/2025 and expires on 09/30/2035. The filing reports that the option was issued as payment for $18,750 in director fees under the issuer's 2024 Equity Incentive Plan. After this grant, Ms. Bray beneficially owns 1,164,025 shares of Biolargo common stock, held directly. The Form 4 was executed on 10/02/2025 and filed under Section 16 reporting requirements.
Marshall Dennis E, a director of Biolargo, Inc. (BLGO), reported option grants on 09/30/2025. Two options to purchase common stock were acquired: 132,351 shares exercisable at $0.17 per share (expiring 09/30/2035) and 110,294 shares exercisable at $0.17 per share (expiring 09/30/2035). The first option replaces a previously issued option for 34,615 shares that expired unexercised; the replacement was made under the issuer’s Compensation Committee plan in lieu of $22,500 in services. The second option was issued as payment of $18,750 in board fees under the 2024 Equity Incentive Plan. Following the reported grants, beneficial ownership figures shown are 4,957,267 and 5,067,561 shares on the respective lines. The Form 4 was signed by attorney-in-fact John R. Browning on 10/02/2025.
FAQ
What is the current stock price of Biolargo (BLGO)?
What is the market cap of Biolargo (BLGO)?
